论文部分内容阅读
应用人白细胞干扰素α（ｈＩＦＮα）治疗肾综合征出血热（ＨＦＲＳ）２３例，基因工程干扰素α２ｂ（ｒＩＦＮα２ｂ）治疗ＨＦＲＳ２１例，均收到良好的疗效。与对照组相比，干扰素治疗组三痛消失较快，球结膜水肿消退较早，尿蛋白持续时间缩短，血尿素氮（ＢＵＮ）峰值减低，多尿期提前出现，血小板计数较快恢复正常，严重出血及继发感染等并发症明显减少，病毒膜蛋白（ＭＰ）和核蛋白（ＮＰ）在外周血单个核细胞（ＰＢＭＣ）中的表达迅速减弱，从小便排出的时间也明显缩短，血清抗－ＭＰ水平下降。结果提示，干扰素能抑制肾综合征出血热病毒（ＨＦＲＳＶ）在ＰＢＭＣ中复制和表达其结构蛋白，从而减轻病情
23 cases of hemorrhagic fever with renal syndrome (HFRS) were treated with human IFN-α (hIFNα) and 21 cases of HFRS treated with IFNα2b (genetically engineered interferon α2b). Compared with the control group, the three pain disappeared quickly in the interferon group, the conjunctival edema faded earlier, the duration of urinary protein shortened, the peak of BUN decreased, the appearance of polyuria appeared earlier and the platelet count returned to normal quickly , Serious complications such as severe hemorrhage and secondary infection were significantly reduced. The expression of viral membrane protein (MP) and nuclear protein (NP) in peripheral blood mononuclear cells (PBMCs) rapidly decreased, and the time from urination was significantly shortened. Serum Anti-MP levels decreased. The results suggest that interferon inhibits the replication and expression of the structural protein of hemorrhagic fever with renal syndrome virus (HFRSV) in PBMC, thereby alleviating the disease